1.37 0.04 (3.01%) | 02-12 16:02 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 1.92 ![]() |
1-year : | 2.19 ![]() |
Resists | First : | 1.65 ![]() |
Second : | 1.87 ![]() |
Pivot price | 1.49 ![]() |
|||
Supports | First : | 1.28 ![]() |
Second : | 1.06 ![]() |
MAs | MA(5) : | 1.37 ![]() |
MA(20) : | 1.53 ![]() |
MA(100) : | 2.17 ![]() |
MA(250) : | 2.78 ![]() |
|
MACD | MACD : | -0.2 ![]() |
Signal : | -0.2 ![]() |
%K %D | K(14,3) : | 9 ![]() |
D(3) : | 5.2 ![]() |
RSI | RSI(14): 32.8 ![]() |
|||
52-week | High : | 5.09 | Low : | 1.28 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ABOS ] has closed above bottom band by 17.5%. Bollinger Bands are 33.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 1.39 - 1.4 | 1.4 - 1.41 |
Low: | 1.26 - 1.27 | 1.27 - 1.28 |
Close: | 1.35 - 1.37 | 1.37 - 1.39 |
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Tue, 11 Feb 2025
ABOS stock touches 52-week low at $1.31 amid market challenges - MSN
Wed, 05 Feb 2025
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Update - MarketBeat
Fri, 31 Jan 2025
Acumen Pharmaceuticals chief medical officer sells $5,118 in shares - MSN
Wed, 29 Jan 2025
Acumen Pharmaceuticals chief legal officer sells shares worth $5,434 - MSN
Fri, 24 Jan 2025
Matt Zuga Sells 28,902 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Stock - MarketBeat
Thu, 23 Jan 2025
Brokers Offer Predictions for ABOS FY2025 Earnings - MarketBeat
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 60 (M) |
Shares Float | 32 (M) |
Held by Insiders | 11.2 (%) |
Held by Institutions | 78.4 (%) |
Shares Short | 1,830 (K) |
Shares Short P.Month | 1,430 (K) |
EPS | -1.38 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 3.61 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -21 % |
Return on Equity (ttm) | -32.9 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | -1.21 |
Sales Per Share | 0 |
EBITDA (p.s.) | -1.55 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -67 (M) |
Levered Free Cash Flow | -42 (M) |
PE Ratio | -1 |
PEG Ratio | 0 |
Price to Book value | 0.37 |
Price to Sales | 0 |
Price to Cash Flow | -1.23 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |